To identify molecular mediators of Jade-1 activity, we screened a human kidney cDNA library with a yeast two-hybrid approach using a transcriptionally inactive truncation of Jade-1 lacking both PHDs (Jade-1 dd) as bait (
Supplementary Information, Fig. S1a). Nine strong interactors were found, including β-catenin, an oncoprotein and the key transcriptional co-activator of canonical Wnt signaling
7.
The Jade-1-β-catenin interaction was confirmed in mammalian cells by coimmunoprecipitation (). The localization and fate of β-catenin depend on Wnt status
7. Constitutively, in Wnt-off phase, β-catenin is phosphorylated by GSK-3β, binds to the destruction complex in the cytosol and gets degraded. In Wnt-on phase, GSK-3β is inhibited; β-catenin dissociates from the destruction complex and translocates to the nucleus. We therefore examined the binding of endogenous Jade-1 and β-catenin during the different states of Wnt signaling. Wnt signaling was activated using Wnt-3a ligand or lithium chloride (an inhibitor of GSK-3β that mimics Wnt activation) and inhibited using Wnt-3a plus DKK1, a competitive antagonist of Wnt-3a ( and
Supplementary Information, Fig. S1b). Endogenous Jade-1 co-immunoprecipitated with endogenous β-catenin and vice-versa (). However, the Jade-1-β-catenin interaction was increased in vehicle and Wnt-3a-DKK1 treated cells (Wnt-off phase) compared with Wnt-3a treated cells (Wnt-on phase). Co-localization and profile plots were performed to demonstrate the distribution and abundance of the proteins (). In Wnt-off phase (, Vehicle treated), β-catenin was predominantly in the cytosol and cell membrane. Jade-1 was in the cytosol and nucleus, exclusive of nucleoli
3,8. Co-localization of Jade-1 and β-catenin was found in the cytosol. Wnt-3a treatment resulted in nuclear translocation of β-catenin. However, Jade-1 and β-catenin exhibited different sub-compartmental localization in the nucleus (, Wnt-3a treated), resulting in reduction in co-localization. Thus, endogenous Jade-1 and endogenous β-catenin interact, and the interaction is greater in Wnt-off phase than in Wnt-on phase.
Jade-1 specifically interacted with the N terminus of β-catenin (). Interestingly, Jade-1 showed reduced binding to a naturally occurring, cancer-causing, constitutively active (CA) S33A mutant of β-catenin lacking this GSK-3β phosphorylation site (). These findings were confirmed by immunofluorescence microscopy of cells expressing Flag-tagged Jade-1 and a Myc-tagged β-catenin series (
Supplementary Information, Fig. S1c-e). In Wnt-off phase, Jade-1 co-localized extensively with wild-type β-catenin and the C terminus truncation of β-catenin predominantly in cytosol, but not with β-catenin S33A or the N terminus truncation of β-catenin (
Supplementary Information, Fig. S1d). In contrast in Wnt-on phase, wild-type β-catenin localized to the nucleus, thereby reducing co-localization with Jade-1 (
Supplementary information, Fig. S1d versus S1e), consistent with the reduction in endogenous Jade-1-β-catenin binding with Wnt activation. These data indicate that β-catenin N-terminal serine residue 33, or its phosphorylation, is important for optimal binding to Jade-1. We examined the binding of purified recombinant GST-tagged Jade-1 and GST-tagged β-catenin in
in vitro GST pull-down assays. GST-tagged Jade-1 associated with GST-tagged β-catenin (
Supplementary Information, Fig. S1f). However, this binding was substantially increased after
in vitro phosphorylation of β-catenin by kinases CK1 and GSK-3β (
Supplementary Information, Fig. S1f). GST-tagged Jade-1 did not bind to the N terminus deletion of β-catenin. Overall, Jade-1 directly binds the N terminus of β-catenin, and the interaction is enhanced with β-catenin phosphorylation in Wnt-off phase.
In Wnt-off phase, β-catenin undergoes degradation, a process that depends on the β-catenin N terminus or ‘degron’
7,9. Jade-1 interacts with the N terminus of β-catenin and, in particular, residue S33, (
Supplementary Information, Fig. S1a). We therefore examined whether Jade-1 regulates β-catenin abundance. Jade-1 down-regulated wild-type β-catenin and a C terminus deletion (). However, Jade-1 had little effect on an N terminus deletion of β-catenin or β-catenin S33A, consistent with the binding pattern of Jade-1 with β-catenin ().
Endogenous β-catenin exists in three distinct cellular pools
7. Endogenous β-catenin protein in the cytosolic and nuclear fractions was at least 2-fold higher in 3 different
Jade-1 silenced cell lines than in empty vector lines ( and
Supplementary Information, Fig. S2b-S2d). The membrane pool of β-catenin was unchanged. Conversely, the amount of β-catenin in the cytosolic and nuclear fractions was substantially lower in Jade-1-expressing stable cell lines than in the empty vector cell lines (). We then examined the half-life of cytosolic β-catenin. A digitonin-extracted fraction
10 was enriched for cytosol, as evidenced by the increase in cytosolic markers, but had no membrane contamination (
Supplementary Information, Fig. S2e). The half-life of the digitonin-extracted cytosolic β-catenin was increased from 10 mins to 90 mins in
Jade-1 silenced 293 cell lines (). Thus,
Jade-1 silencing substantially stabilized cytosolic β-catenin. β-catenin half-life was reduced in the Jade-1-expressing renal cancer cell lines (
Supplementary Information, Fig. S2f). Thus, Jade-1 regulates the stability of the Wnt-responsive pool of β-catenin.
β-catenin degradation depends on GSK-3β. In Wnt-off phase, β-catenin undergoes sequential phosphorylation at threonine 41 and serine 37 and 33 by GSK-3β. Preferential binding of Jade-1 to phospho-β-catenin and lack of binding to β-catenin S33A suggest a possible role for GSK-3β in Jade-1 regulation of β-catenin ( and
Supplementary Information, Fig. S1f). Moreover, full-length Jade-1 reduced total β-catenin due predominantly to reduction in phospho-β-catenin (
Supplementary Information, Fig. S3a). Thus, Jade-1 preferentially regulates phospho-β-catenin. This observation further suggests that GSK-3β may be particularly important for Jade-1 regulation of β-catenin. Indeed, Jade-1 regulation of β-catenin was mitigated by silencing or chemical inhibition of GSK-3β (). Similarly, the effect of
Jade-1 silencing on β-catenin abundance was reduced in Wnt-on phase, when GSK-3β activity is inhibited ( and
Supplementary Information, Fig. S3b). Overall, these data indicate that Jade-1 requires intact GSK-3β kinase activity for full inhibition of β-catenin.
β-catenin undergoes proteasomal degradation
11. Proteasome inhibition with MG132 completely abrogated the effect of Jade-1 on β-catenin abundance (
Supplementary Information, Fig. S3c). Moreover, in the presence of Jade-1 and proteasomal inhibition, very high molecular weight species of β-catenin accumulated (
Supplementary Information, Fig. S3d), suggesting that Jade-1 may enhance ubiquitination and degradation of β-catenin.
Protein ubiquitination depends on substrate recognition by a highly selective E3 ubiquitin ligase. PHD proteins such as MEKK1 and MIR exhibit E3 ubiquitin ligase activity
12,13. Jade-1 has two PHDs
3 that align well with the PHDs of MEKK1, MIR1, MIR2 and c-MIR (
Supplementary Information, Fig. S4a). Therefore, we reasoned that Jade-1, through its PHDs, might ubiquitinate β-catenin. Deletion of the PHDs reduced the effect of Jade-1 on β-catenin (
Supplementary Information, Fig. S4b). Next, endogenous β-catenin was immunoprecipitated, and its ubiquitination was examined in the presence of Myc-tagged ubiquitin and Jade-1, Jade-1 dd or the well-established β-catenin E3 ubiquitin ligase component β-TrCP
6 (). Minimal β-catenin ubiquitination was observed with β-TrCP under these conditions, possibly due to lower expression of β-TrCP or the fact that the other components of the β-TrCP SCF complex were not co-expressed. Interestingly, robust β-catenin polyubiquitination was observed with full-length Jade-1, while deletion of the PHDs substantially reduced β-catenin ubiquitination (). β-catenin ubiquitination appeared as a smear, most prominently in the presence of full-length Jade-1. Since 293T cells are in Wnt-off status under basal conditions, these data indicate that Jade-1 promotes endogenous β-catenin ubiquitination in Wnt-off phase.
In vitro ubiquitination of β-catenin was then examined. GST-purified β-catenin was incubated with HeLa cell cytosolic S100 fraction. β-catenin ubiquitination was observed in the presence of Jade-1 (). To address if Jade-1 directly ubiquitinates β-catenin and to map the E3 ubiquitin ligase domain within Jade-1, we reconstituted ubiquitination reactions with all purified components ( and
Supplementary Fig. S4c). β-catenin ubiquitination was observed with Jade-1 in a dose-dependent manner (
Supplementary Information, Fig. S4c, lanes 4-6). Deletion of the Jade-1 PHDs or the β-catenin N terminus abrogated β-catenin ubiquitination (, lanes 5 and 10; and
Supplementary Information, Fig. S4c, lanes 7 and 12). Thus, purified Jade-1 ubiquitinates non-phosphorylated GST-tagged β-catenin, and the Jade-1 PHDs are necessary for E3 ubiquitin ligase activity.
In order to examine the relationship between Jade-1- and β-TrCP-mediated β-catenin degradation, DN β-TrCP lacking the F box was used to antagonize both β-TrCP1 and β-TrCP2
14. DN β-TrCP increased endogenous β-catenin expression by 2 fold (). Interestingly, Jade-1 could still down-regulate β-catenin in the presence of DN β-TrCP (), which suggests that Jade-1 regulates β-catenin independently of β-TrCP.
The biological significance of the Jade-1-β-catenin interaction was evaluated in TCF/β-catenin transcription assays. Full-length Jade-1, but not Jade-1 dd, inhibited a TOP-Flash promoter-reporter by 3.5 fold (). Jade-1 had no effect on β-catenin S33A transcriptional activity (). These observations are consistent with the effect of Jade-1 on protein levels of wild-type β-catenin and β-catenin S33A (). Intriguingly, significant inducible endogenous Wnt activity was observed in
Jade-1 silenced cell lines (
Supplementary information, Fig. S5a), consistent with the stabilization of endogenous β-catenin in these lines.
Since Jade-1 destabilizes β-catenin and inhibits β-catenin-mediated transactivation, we reasoned that Jade-1 might inhibit the canonical Wnt pathway
in vivo. We used a functional assay for canonical Wnt signaling, formation of an ectopic axis in
Xenopus laevis embryos by ventral injection of
Xwnt-8 or
β-catenin mRNA
15. Full-length
Jade-1, but not
Jade-1 dd, significantly inhibited both
Xwnt-8- and
β-catenin-induced ectopic axis formation in developing
Xenopus laevis embryos ( and
Supplementary Information, Fig. S5b). These data suggest that Jade-1 has the capacity to suppress Wnt activity during Wnt-on phase
in vivo. This is plausible in view of the appreciable interaction of Jade-1 and β-catenin in Wnt-on phase ( and
Supplementary Information Fig. S1b) and Jade-1 binding and ubiquitination of non-phosphorylated β-catenin (
Supplementary Information, Fig. S1f and ). The specific Wnt target Axin2
16 was also increased in
Jade-1 silenced 293 cell lines (). Other Wnt targets, such as cyclin D1 and c-Myc, were increased in
Jade-1 silenced cell lines (
Supplementary Information, Fig. S5c). Full-length Jade-1, but not Jade-1 dd, reduced protein levels of c-Myc (
Supplementary Information, Fig. S5d). Thus, Jade-1 is an inhibitor of canonical Wnt signaling.
Jade-1 protein is stabilized by wild-type pVHL, but not by mutated pVHL associated with renal cancer
3,4. We hypothesized that pVHL might regulate β-catenin through Jade-1. First, we compared β-catenin abundance in
VHL-deficient and
VHL-intact renal cancer cell lines (). Interestingly, endogenous cytosolic and nuclear pools of β-catenin were several-fold lower in
VHL-intact cell lines compared to
VHL-deficient cell lines (). This result can be explained on the basis of our previous observations that Jade-1 levels are significantly lower in
VHL-deficient cell lines
5. Next, pVHL reintroduction in 786-O cells increased endogenous Jade-1
4,5. and substantially reduced endogenous β-catenin levels ( and
Supplementary Information, Fig. S6a). Knock-down of
VHL with siRNA oligonucleotides resulted in down-regulation of Jade-1 and accumulation of β-catenin ( and
Supplementary Information, Fig. S6b)
17.
To specifically examine whether Jade-1 mediates pVHL down-regulation of β-catenin, we compared β-catenin regulation by wild-type pVHL and by truncated forms of pVHL that do not stabilize Jade-1
4(). pVHL del96-122 and naturally occurring, cancer-causing truncations like pVHL 1-143 and pVHL 1-175, which have little or no effect on Jade-1 stability
4, had minimal effect on β-catenin (). We also knocked down
Jade-1 in the presence of pVHL. Endogenous Jade-1 levels were increased by pVHL, an effect blocked by
Jade-1 knock-down (
Supplementary Information, Fig. S6c). Importantly, down-regulation of β-catenin by pVHL was substantially mitigated by
Jade-1 knock-down (
Supplementary Information, Fig. S6c). Furthermore, pVHL wild-type, but not pVHL del96-122, suppressed β-catenin transcriptional activity (
Supplementary Information, Fig. S6d). Specific Wnt targets such as LEF1
18 and cyclin D1 were reduced in pVHL-expressing renal cancer cell lines (). Wild-type pVHL, but not pVHL del96-122, also reduced Axin2 in 293T cells (
Supplementary Information, Fig. S6e). Overall, these data indicate that pVHL inhibits β-catenin and canonical Wnt signaling and that Jade-1 is a critical mediator of these effects.
To determine if pVHL is able to reduce endogenous Wnt signaling
in vivo, and to examine the difference in the suppression of Wnt activity by wild-type pVHL and pVHL del96-122, we injected
wild-type VHL or
VHL del96-122 mRNA into the dorsal blastomeres of
Xenopus laevis embryos, in which canonical Wnt signaling is necessary for dorsal development
19. Inhibition of dorsal axis formation in
Xenopus laevis embryos is evidenced by reduction of dorsoanterior structures (small eyes, microcephaly, or anencephaly) measured with a dorsoanterior index (DAI) scale
19. Wild-type pVHL suppressed dorsal axis formation significantly more than pVHL del96-122 at the same level of protein abundance (
Supplementary Information, Figs. S6f and S6g). As expected, inhibition of endogenous axis by wild-type pVHL was associated with greater suppression of β-catenin/Tcf target genes
Xsiamois and
Xnr3 than by pVHL del96-122 (). Thus, pVHL inhibits canonical Wnt signaling
in vivo, and pVHL del96-122, which binds and regulates Jade-1 only minimally
4,5, had little effect on dorsal axis formation and Wnt target genes in
Xenopus laevis embryos. These data further support the role of Jade-1 as a critical mediator of pVHL regulation of β-catenin.
In this study, we have demonstrated that Jade-1 is a single-subunit E3 ubiquitin ligase for β-catenin and that the Jade-1 PHDs are essential for E3 ubiquitin ligase function. Moreover, Jade-1 is a critical mediator of pVHL inhibition of β-catenin and canonical Wnt signaling. Jade-1 is anti-proliferative and pro-apoptotic, while β-catenin is pro-proliferative, anti-apoptotic and oncogenic
7. Therefore, the tumor suppressor activity of Jade-1 may be due in part to inhibition of β-catenin.
Several ubiquitin ligases for β-catenin have now been identified
9,20,21, but only β-TrCP and Jade-1 show Wnt responsiveness, suggesting they are both important in the physiology and pathophysiology of canonical Wnt signaling. Endogenous β-TrCP resides in the cytosol and is capable of binding and ubiquitinating phosphorylated β-catenin
6,9,22,23. In contrast, endogenous Jade-1 resides in the cytosol but is found primarily in the nucleus
3,8 and is capable of binding and ubiquitinating both phosphorylated and non-phosphorylated β-catenin. Thus, Jade-1 and β-TrCP have only partially overlapping subcellular locations and have differing specificities for the forms of β-catenin. These differences may explain why
Jade-1 silencing cannot be completely compensated for by β-TrCP ( and
Supplementary Information, Figs. S2b-d). Moreover, Jade-1 seems to act more distally in the canonical Wnt cascade, affecting β-catenin in the nucleus. This may make Jade-1 responsible for fine control of β-catenin levels.
Jade-1 functions as a single-subunit E3 ubiquitin ligase for β-catenin, whereas β-TrCP requires formation of a multi-subunit protein complex. The PHD functions as an adaptor-type E3 ubiquitin ligase directly transferring the ubiquitin moiety to the substrate
13. Control of Jade-1 may therefore be a simpler and perhaps more efficient way of regulating β-catenin abundance. It is likely that the cell exploits the distinct functional and contextual differences between β-TrCP and Jade-1 to ensure effective regulation of Wnt signaling.
β-catenin is emerging as a key molecule in the pathogenesis of renal cancer and renal cystic disease. For example, increased β-catenin activity in renal epithelium in mice results in robust renal cyst and tumor formation
24-26. In renal cancer, methylation of the
APC gene promoter is common
27. pVHL was recently shown to inhibit HGF-mediated tyrosine phosphorylation of β-catenin
28. These observations further strengthen the role of Wnt signaling in renal-cell carcinoma. Jade-1 and pVHL may also participate in other forms of cystic kidney disease, in which evidence of dysregulated Wnt signaling is mounting
26,29.
Our data suggest that Jade-1 inhibition of Wnt signaling represents a new tumor suppressor axis for pVHL. Furthermore, these findings directly link the kidney-specific pVHL tumor suppressor pathway and the Wnt signaling cascade, a more general tumorigenesis pathway. Jade-1 and beta-catenin may therefore represent therapeutic targets in renal-cell carcinoma.